The Use of Biomarkers in Early Diagnostics of Pancreatic Cancer

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F18%3A00068709" target="_blank" >RIV/65269705:_____/18:00068709 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216224:14110/18:00103475

Výsledek na webu

<a href="https://www.hindawi.com/journals/cjgh/2018/5389820/" target="_blank" >https://www.hindawi.com/journals/cjgh/2018/5389820/</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1155/2018/5389820" target="_blank" >10.1155/2018/5389820</a>

Jazyk výsledku

angličtina

Název v původním jazyce

The Use of Biomarkers in Early Diagnostics of Pancreatic Cancer

Popis výsledku v původním jazyce

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal solid malignancies with increasing incidence. The poor prognosis is due to the aggressive nature of the tumor, late detection, and the resisance to chemotherapy and radiotherapy. A radical surgery procedure is the only treatment that has been shown to improve the 5-year survival rate to 20-25%. However, the majority of patients (80-85%) are diagnosed with locally advanced or metastatic disease and just 15-20% patients are diagnosed in an early stage allowing them to undergo the potentially curatice surgical resection. The early detection of PDAC without the use of invasive methods is challenging and discovery of a cost-effective biomarker with high specifity and sensitivity could significantly improve the treatment and survival in these patients. In this review, we summarize current and newly examined biomarkers in early PDAC detection.

Název v anglickém jazyce

The Use of Biomarkers in Early Diagnostics of Pancreatic Cancer

Popis výsledku anglicky

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal solid malignancies with increasing incidence. The poor prognosis is due to the aggressive nature of the tumor, late detection, and the resisance to chemotherapy and radiotherapy. A radical surgery procedure is the only treatment that has been shown to improve the 5-year survival rate to 20-25%. However, the majority of patients (80-85%) are diagnosed with locally advanced or metastatic disease and just 15-20% patients are diagnosed in an early stage allowing them to undergo the potentially curatice surgical resection. The early detection of PDAC without the use of invasive methods is challenging and discovery of a cost-effective biomarker with high specifity and sensitivity could significantly improve the treatment and survival in these patients. In this review, we summarize current and newly examined biomarkers in early PDAC detection.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30219 - Gastroenterology and hepatology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2018

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Canadian Journal of Gastroenterology and Hepatology

ISSN

2291-2797

e-ISSN

—

Svazek periodika

2018

Číslo periodika v rámci svazku

AUG 2018

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

10

Strana od-do

5389820

Kód UT WoS článku

000442877300001

EID výsledku v databázi Scopus

2-s2.0-85052611027